Delivery Order SPE2DB24D1007-SPE2DB25FCCPF
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a ceiling value of $11,089.97. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for ultimate completion on September 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,376.58 to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 10 mg tablets (30-count packaging) on August 4, 2025, with completion targeted for August 5, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30, with a contract ceiling value of $5,097.35. This is a firm fixed-price delivery order with an ultimate completion date of September 10, 2025, and represents a non-set-aside competitive award. The delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dapagliflozin 10 mg tablets in a 30-count package at a ceiling value of $1,333.77. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 21, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 14, 2025, for the supply of Dapagliflozin 5 mg tablets (30-count) with a contract value of $1,224.06 and a completion date of October 15, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 10, 2025, for the supply of Dapagliflozin 5 mg tablets (30-count units) valued at $10,269.40 under a firm fixed price contract. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical product will be delivered...
- The Defense Logistics Agency (DLA) awarded a $5,346.26 delivery order to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 10 mg tablets (30-count units) on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a delivery order, indicating it is issued under a larger indefinite delivery contract (IDC) vehicle. The pharmaceutical product will be delivered to the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count packaging) with a ceiling value of $7,971.96. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procedures. The order is scheduled for ultimate completion on August 27, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a ceiling value of $5,358.11 and a firm fixed price structure. The contract represents a non-set-aside, competitively awarded delivery order with an ultimate completion date of July 25, 2025. This award is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a contract ceiling value of $10,763.89. This firm fixed-price delivery order, which reaches ultimate completion on August 14, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively awarded with no set-aside...
- SPE2DB24D1007Indefinite Delivery Contract
- SPE2DB24D1007-SPE2DB25FCCPFDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Dapagliflozin 5 mg tablets (30-count packages) with a ceiling value of $1,200.23. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The order is scheduled for completion by July 24, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical support vehicle running through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement supporting military and veteran healthcare systems. The company's portfolio with the DLA encompasses a broad range of pharmaceutical products across multiple therapeutic domains, including diabetes medications, neurological treatments, pain management pharmaceuticals, and specialized medical supplies. Dapagliflozin is a diabetes medication commonly used to treat type 2 diabetes and heart failure, reflecting the company's role in supplying essential medications to support military healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 7/23/25 |